MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II drugs for Hidradenitis Suppurativa have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MC-232’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MC-232 overview

MC-232 is under development for the treatment of plaque psoriasis, bullous pemphigoid, hidradenitis suppurativa, atopic dermatitis. The drug candidate is administered topically and orally . It was under development for the treatment of  non-small cell lung cancer, metastatic renal cell carcinoma and lymphomas. It is a synthetic small molecule that acts by targeting heat shock protein 90 (Hsp90). It is developed based on Heat Shock Protein (Hsp90) technology.

MC2 Therapeutics overview

MC2 Therapeutics is a privately held emerging pharmaceutical company. The company is headquartered in Hørsholm, Hovedstaden, Denmark.

For a complete picture of MC-232’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.